EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus <br clear="all" /> Core Inhibitor: Results of a 28-day Phase 1b Study in NUC-suppressed CHB Patients

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022


EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Results of a 28-day Phase 1b Study in NUC-suppressed CHB Patients

	EASL 2022 June 22-26